Oct 07, 2012 - 5:37 am
Along my journey of twelve years with prostate cancer I have been amazed with the so many researches in course at the labs of super scientists, particularly what has been found and done at genes level (I read hundreds of papers). In fact our problem starts exactly from there and an overexpression of some identified genes means the misfortune for some of us.
Pathologists try to identify the type of each cell in our diagnosis and such could identify the extent of our disease. It could differentiate between the ones that are more or may not be prune to metastases.
An overexpression of the Myelocytomatosis (MYC) oncogene in cancer cells, is associated with poor clinical outcomes, including increased rates of metastasis, recurrence, and mortality.
In studies done at Johns Hopkins, the pathologist Dr. De Marzo found that MYC also drives a nucleolar program of gene expression in prostate cancer particularly the overexpression of the key prostate cancer progression gene, EZH2.
A precise hit on MYC would be the target of a magic “Silver bullet” drug.
Professor Peter Rahl from Young lab says this;
Here are two links of articles on the subject that my comrades may like to follow;
A breeze of Hope to everyone.